Goldman Sachs Group Inc Codiak Bio Sciences, Inc. Transaction History

Goldman Sachs Group Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$2.24 - $6.96 $48,950 - $152,096	21,853 New	21,853 $63,000
Q2 2022 Aug 15, 2022	SELL	$2.24 - $6.96 $30,717 - $95,442	-13,713 Reduced 38.56%	21,853 $63,000
Q1 2022 May 16, 2022	BUY	$4.3 - $12.95 $152,933 - $460,579	35,566 New	35,566 $223,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.